Tripathi A, Ditto A M, Grammer L C, Greenberger P A, McGrath K G, Zeiss C R, Patterson R
Department of Medicine of Northwestern Memorial Hospital, Northwestern University Medical School, Chicago, Illinois 60611, USA.
Allergy Asthma Proc. 2000 Mar-Apr;21(2):101-5. doi: 10.2500/108854100778250914.
Stevens-Johnson syndrome (SJS) is a severe cutaneous eruption that can be a life-threatening emergency. Previously, we have reported our favorable experience in treating 54 patients with SJS with systemic corticosteroids. We continued our prospective analysis of consecutive patients with SJS treated with corticosteroids. Possible etiologic factors and clinical outcomes of the patients are described. All 13 patients improved with initiation of systemic corticosteroid therapy. There was no mortality or permanent sequelae attributable to SJS. Drugs were the offending agents in all 13 cases. There was one death unrelated to SJS. In conclusion, prompt treatment with systemic corticosteroids reduces morbidity and improves outcome of SJS patients. This analysis extends our series to 67 consecutive patients with SJS who were treated with corticosteroids and had a favorable outcome.
史蒂文斯-约翰逊综合征（SJS）是一种严重的皮肤疹，可能是危及生命的急症。此前，我们报道了用全身性皮质类固醇治疗54例SJS患者的良好经验。我们继续对接受皮质类固醇治疗的连续性SJS患者进行前瞻性分析。描述了患者可能的病因和临床结果。所有13例患者在开始全身性皮质类固醇治疗后病情均有改善。没有因SJS导致的死亡或永久性后遗症。在所有13例病例中，药物是致病因素。有1例死亡与SJS无关。总之，及时用全身性皮质类固醇治疗可降低SJS患者的发病率并改善其预后。该分析将我们的系列研究扩展至67例连续性接受皮质类固醇治疗且预后良好的SJS患者。
